

Mold-Tek Packaging (MTEP)

Packaging | Company Update

BUY

CMP: Rs846 | Target Price (TP): Rs1,100 | Upside: 30%

March 06, 2024

Deep dive into Pharma Packaging opportunity

Key Points

- We reiterate our Buy call on MTEP after rolling forward valuation to FY26E (PE 30x) with a potential upside of 30%.
- In this report, we are discussing Indian Pharma Packaging opportunity, competitive landscape & MTEP's 'right to win'. We believe MTEP could be a one-stop shop for Pharma plastic packaging over the medium term.
- Backward integration, ever increasing TAM and margin-accretive projects on hand differentiate MTEP from others.

One-stop shop could be the biggest 'right to win': In-house production of the entire range of Pharma plastic packaging portfolio (Bottles, Caps, CRC, Effervescent Tubes & Cartridges) should enable MTEP to become a 'one-stop shop for Pharma Packaging. Introduction of IML in the Pharma, ability to offer the entire range with higher efficiency & lead times, presence in close proximity for South-based companies and increasing USFDA registrations in India should lead to relatively faster order conversions, in our view.

Regulated Pharma Packaging market has high entry barriers: While MTEP is planning to cater to regulated pharma (DMF backed packaging) as well as domestic generic players, our channel checks with some of the regional packaging players suggest that entering the DMF market is very difficult for small players because of high gestation period and oligopolistic nature of the business. Also, capturing customers' mind and wallet share is very tricky in the Pharma business. MTEP's backward integration, multiple new offerings apart from the existing products offered by competition and low import dependence should enable it to crack the concentrated market.

Import substitution, better inventory management & lead time: We highlight that currently India imports ~Rs2.25bn worth of stoppers, lids, caps and closures annually. While this has multiple applications apart from Pharma, such as in Cosmetics, Beverages, Textiles etc., we see MTEP's peers also importing from USA and Europe in a big way. Gopaldas buys CRC and other caps from MoldRite. Triveni Polymers imports CRC, Dropper and other closures from its subsidiary Gerresheimer Boleslawiec S.A. (Poland, USA & China). On the other hand, MTEP is planning to manufacture everything in-house and we believe that pricing could be competitive as the project scales up. Without import dependence, working capital management (inventory) & lead time should be better than peers.

Peer comparison: Our research suggests that the Pharma Packaging universe (mainly DMF backed) is concentrated. Gross margin profile of all the companies is superior than MTEP's current margin (Pharma IBM Per/kg margin > 50%, as per management). Working capital cycle is broadly similar. We believe that MTEP can bring in more operational efficiencies than peers.

Please vote for us in the Institutional Investor poll – [Click Here](#)

Est Change	No change
TP Change	Upward
Rating Change	No change

Company Data and Valuation Summary

Reuters:	MOLT.BO
Bloomberg:	MTEP IN Equity
Mkt Cap (Rsbn/US\$mn):	28.1 / 339.0
52 Wk H / L (Rs):	1,100 / 825
ADTV-3M (mn) (Rs/US\$):	59.9 / 0.7
Stock performance (%) 1M/6M/1yr:	(2.7) / (10.9) / (11.4)
Nifty 50 performance (%) 1M/6M/1yr:	2.3 / 6.6 / 25.9

Shareholding	1QFY24	2QFY24	3QFY24
Promoters	33.3	33.1	32.9
DII's	18.6	18.5	19.2
FII's	18.0	17.8	16.0
Others	30.1	30.6	31.9
Pro pledge	0.2	0.2	0.2

Financial and Valuation Summary

Particulars (Rsmn)	FY23	FY24E	FY25E	FY26E
Net Sales	7,299	7,097	8,717	10,238
Growth YoY%	15.6	-2.8	22.8	17.4
Gross margin %	40.3	39.0	40.0	41.0
EBITDA	1,354	1,356	1,766	2,107
EBITDA margin %	18.6	19.1	20.3	20.6
Adj PAT	804	688	973	1,200
Growth YoY%	26.4	-14.5	41.4	23.3
EPS	24.2	20.8	29.5	36.3
RoCE (pre-tax)%	19.0	15.1	19.2	21.5
RoCE%	14.9	11.3	14.4	16.1
RoE%	15.8	11.9	15.5	17.3
P/E	34.7	40.4	28.6	23.2
EV/EBITDA	20.9	20.8	16.0	13.4
P/BV	5.0	4.6	4.2	3.8

Source: Bloomberg, Company, Nirmal Bang Institutional Equities Research

Key Links – [Annual Report Analysis](#)

Please refer to the disclaimer towards the end of the document.

Innovation game at/above par vs global packaging solutions companies


Apart from backward integration, constant thrust on innovation differentiates MTEP from others, in our view. In its Pharma foray, MTEP can leverage on some of its existing innovative methods such as IML adoption, QR coded IML, IBM technology etc apart from industry-specific innovations. The following examples indicate that MTEP is definitely ahead in the game as far as innovation is concerned. Innovation is among the key factors which should enable a relatively faster entry for MTEP in the specialised Pharma Packaging market dominated by select niche players.

- Sanner GmbH (Germany based MNC) is a global market leader for desiccant closures and effervescent tablet packaging. Sanner has manufacturing presence in Germany, France, Hungary and China. We believe that there are no imports into India. MTEP is the first Indian company to launch IML in effervescent tubes with premium photographic label decoration, non scratchable and non peelable, enhancing the overall aesthetic value.
- Gerresheimer AG (now a subsidiary of Triveni Polymers) is a German manufacturer of primary packaging products for medication and drug delivery devices made of special-purpose glass and plastics with headquarters in Düsseldorf for the Pharma and Cosmetics industries. The company has production operations in Europe, the Americas and Asia. It talks about traceability tool in its innovation programme. We highlight that MTEP has already developed QR coded IML containers (currently for Paints and Lubes customers) and the same can be replicated for the Pharma industry as well.
- An upcoming product, Desiccant Canister, finds its application in moisture absorption in powders and tablets. MTEP is working on a canister with laser marking to ensure child resistance and prevention of ink seepage. Double piece canisters available in the market lack child resistance features, as per our checks. Laser marking technology ensures safety, permanence and precision compared to traditional printing stamping.

One-stop shop could be MTEP's biggest 'right to win' in Pharma

MTEP plans to leverage its 38 years of packaging industry experience by setting up a new facility for Pharma Packaging, including ISO certified clean rooms and US DMF certifications. In-house production of the entire range of Pharma Packaging portfolio (Bottles, Caps, CRC, Effervesant Tubes & Carnisters) should enable MTEP to become a one-stop shop in Pharma Packaging. Introduction of IML in the Pharma industry, ability to offer the entire range with higher operational efficiency & lead times, presence in close proximity for South-based companies and increasing USFDA registrations in India should lead to relatively faster order conversions, in our view.

Exhibit 1: Country-wise facility registrations by USFDA - India tops the list in FY24




Source: Industry, Nirmal Bang Institutional Equities Research

While MTEP is planning to cater to regulated Pharma (DMF backed packaging) as well as domestic generic players, our channel checks with some of the regional packaging players suggest that entering DMF market is very difficult to crack for small players because of high gestation period and oligopolistic nature of the business. Also, capturing customers' mind and wallet share is very tricky in the Pharma business. MTEP's backward integration, multiple new offerings apart from the existing products offered by competition and low import dependence should enable it to crack the concentrated market.

Import substitution, better inventory management & lead time

We highlight that currently India imports ~Rs2.25bn worth of stoppers, lids, caps and closures annually. While this has multiple applications apart from Pharma, such as in Cosmetics, Beverages, Textiles etc., we see MTEP's peers also importing from USA and Europe in a big way. Gopaldas buys CRC and other caps from MoldRite. Triveni Polymers imports CRC, dropper and other closures from its subsidiary Gerresheimer Boleslawiec S.A. (Poland, USA, China). On the other hand, MTEP is planning to manufacture everything in-house and we believe that pricing could be competitive as the project scales up. Without import dependence, working capital management (inventory) and lead time should be better than peers, in our view.

Exhibit 2: Import of caps and closures in India - monthly trend




Source: Commerce Ministry Website, Nirmal Bang Institutional Equities Research

Peer comparison


Our research suggests that the Pharma Packaging universe (mainly DMF backed) is concentrated. Gross margin profile of all the companies is superior than MTEP's current margin (Pharma IBM Per/kg margin > 50%, as per management). Working capital cycle is broadly similar. We believe that MTEP can bring in more operational efficiencies than peers. Some of the peers mentioned below are import dependent for select caps and closures, including CRC caps. MTEP will manufacture everything in-house. Also, we expect better cost management in some of the cost lines such as job work charges, repairs etc.

Exhibit 3: Pharma Packaging universe* reported Revenue/Gross Profit/EBITDA/PAT 9-year CAGR 12%/13%/12%/15% over FY15-FY23




Source: Company, MCA, Nirmal Bang Institutional Equities Research

Exhibit 4: Gross margin of Pharma Packaging peers



Source: Company, MCA, Nirmal Bang Institutional Equities Research

Exhibit 5: EBITDA margin of Pharma Packaging peers




Source: Company, MCA, Nirmal Bang Institutional Equities Research

*Pharma Packaging universe includes Pravesha Packaging, Shriji Polymers, Triveni Polymers and Gopaldas Visram Packaging.


Detailed comparison of Pharma Packaging universe* and MTEP

Exhibit 6: Gross margin




Source: Company, MCA, Nirmal Bang Institutional Equities Research

Exhibit 7: EBITDA margin




Source: Company, MCA, Nirmal Bang Institutional Equities Research

Exhibit 8: PAT margin




Source: Company, MCA, Nirmal Bang Institutional Equities Research

Exhibit 9: OCF




Source: Company, MCA, Nirmal Bang Institutional Equities Research

Exhibit 10: Capex




Source: Company, MCA, Nirmal Bang Institutional Equities Research


Exhibit 11: FCF




Source: Company, MCA, Nirmal Bang Institutional Equities Research

Exhibit 12: Inventory days



Source: Company, MCA, Nirmal Bang Institutional Equities Research

Exhibit 13: Receivable days



Source: Company, MCA, Nirmal Bang Institutional Equities Research

Exhibit 14: Payable days



Source: Company, MCA, Nirmal Bang Institutional Equities Research

Exhibit 15: Working capital days


Source: Company, MCA, Nirmal Bang Institutional Equities Research


Exhibit 16: ROCE (pre-tax)


Source: Company, MCA, Nirmal Bang Institutional Equities Research

Exhibit 17: ROE



Source: Company, MCA, Nirmal Bang Institutional Equities Research

Exhibit 18: ROIC (pre-tax)



Source: Company, MCA, Nirmal Bang Institutional Equities Research

Exhibit 19: Net debt/Equity ratio



Source: Company, MCA, Nirmal Bang Institutional Equities Research

*Pharma Packaging universe includes Pravesha Packaging, Shriji Polymers, Triveni Polymers and Gopaldas Visram Packaging.

Exhibit 20: Quarterly segment performance

Particulars	3QFY22	4QFY22	1QFY23	2QFY23	3QFY23	4QFY23	1QFY24	2QFY24	3QFY24
Revenue/kg IML vs Non-IML									
IML	228	225	245	232	216	214	215	206	205
Non IML	201	190	207	195	181	176	179	168	167
Total Standalone revenue/kg	219	212	230	218	205	200	202	191	192
Revenue/kg segment wise									
Paints	206	197	211	202	189	182	183	176	177
Lubes	203	199	214	204	187	181	185	174	178
F&F	280	272	312	289	264	266	260	241	226
Total Standalone revenue/kg	218	212	230	218	205	200	202	191	192
EBITDA/Kg	43.1	37.9	41.1	40.7	37.6	39.3	38.1	36.6	35.2

Source: Company, Nirmal Bang Institutional EquitiesResearch

Exhibit 21: IML vs Non-IML classification

Particulars	3QFY22	4QFY22	1QFY23	2QFY23	3QFY23	4QFY23	1QFY24	2QFY24	3QFY24
Volume breakup (%)									
IML	65.5	63.2	61.8	62.6	67.4	64.7	64.1	61.9	64.8
Non IML	34.5	36.8	38.2	37.4	32.6	35.3	35.9	38.1	35.2
Revenue breakup (%)									
IML	68.3	67.0	65.7	66.6	71.1	69.0	68.3	66.7	69.4
Non IML	31.7	33.0	34.3	33.4	28.9	31.0	31.7	33.3	30.6
Volume growth (%)									
IML	0.6	9.0	53.4	18.1	5.9	10.6	5.6	4.0	9.7
Non IML	-11.7	-0.8	47.7	0.5	-2.7	3.5	-4.3	6.7	22.9
Revenue growth (%)									
IML	25.3	13.2	61.7	22.1	0.4	5.1	-7.1	-7.8	4.3
Non IML	10.2	5.4	44.9	1.7	-12.2	-4.4	-17.3	-8.2	13.5


Source: Company, Nirmal Bang Institutional EquitiesResearch

Exhibit 22: Industry-wise classification

Particulars	3QFY22	4QFY22	1QFY23	2QFY23	3QFY23	4QFY23	1QFY24	2QFY24	3QFY24
Volume breakup (%)									
Paints	57.5	55.7	53.4	58.1	50.3	51.7	47.8	50.8	44.3
Lubes	24.8	25.5	28.6	23.7	28.2	26.4	28.0	24.6	26.3
F&F	17.8	18.8	18.1	18.2	21.5	21.9	24.2	24.6	29.4
Revenue breakup (%)									
Paints	54.2	51.9	48.9	53.8	46.5	47.0	43.3	46.6	40.9
Lubes	23.0	24.0	26.6	22.1	25.8	23.9	25.7	22.4	24.5
F&F	22.7	24.1	24.5	24.1	27.7	29.1	31.1	30.9	34.7
Volume growth (%)									
Paints	-6.3	-4.4	38.4	0.8	-10.0	0.3	-8.8	-8.1	0.4
Lubes	-1.1	16.5	80.1	26.5	17.3	11.9	-0.1	9.0	6.3
F&F	-0.2	25.9	53.9	31.1	24.7	25.9	36.1	41.8	56.1
Revenue growth (%)									
Paints	16.7	3.0	43.3	3.9	-17.2	-7.6	-20.8	-20.3	-6.1
Lubes	22.6	23.8	86.5	31.2	7.9	1.6	-13.6	-6.7	1.5
F&F	25.6	16.1	53.1	28.2	17.4	23.0	13.2	18.2	34


Source: Company, Nirmal Bang Institutional EquitiesResearch

Exhibit 23: EBITDA/kg quarterly trend




Source: Company, Nirmal Bang Institutional Equities Research

Exhibit 24: Segment-wise volume share




Source: Company, MCA, Nirmal Bang Institutional Equities Research

Exhibit 25: Segment-wise revenue share




Source: Company, MCA, Nirmal Bang Institutional Equities Research

Exhibit 26: EBITDA/kg annual trend




Source: Company, Nirmal Bang Institutional Equities Research

Exhibit 27: Revenue CAGR- we are building in 18% CAGR over FY24E-26E




Source: Company, Nirmal Bang Institutional Equities Research

Exhibit 28: EBITDA CAGR- we are building in 25% CAGR over FY24E-26E



Source: Company, Nirmal Bang Institutional Equities Research

Exhibit 29: Earnings CAGR- we are building in 22% CAGR over FY24E-26E



Source: Company, Nirmal Bang Institutional Equities Research

Exhibit 30: Change in earnings estimates


Standalone (Rsmn)	Old Estimates			New estimates			Change (%)		
	FY24E	FY25E	FY26E	FY24E	FY25E	FY26E	FY24E	FY25E	FY26E
Revenue	7,097	8,717	10,238	7,097	8,717	10,238	-	-	-
EBITDA	1,356	1,766	2,107	1,356	1,766	2,107	-	-	-
EBITDA margin %	19.1%	20.3%	20.6%	19.1%	20.3%	20.6%	-	-	-
APAT	688	973	1,200	688	973	1,200	-	-	-

Source: Nirmal Bang Institutional Equities Research

Exhibit 31: Scneario Analysis

Particulars (Rsmn)	Current assumptions							Bull-case scenario							Bear-case scenario						
	FY24e	FY25e	FY26e	FY27e	FY28e	FY29e	FY30e	FY24e	FY25e	FY26e	FY27e	FY28e	FY29e	FY30e	FY24e	FY25e	FY26e	FY27e	FY28e	FY29e	FY30e
Volumes (tonnes)	36,257	43,557	49,956	57,133	65,564	75,562	87,522	36,864	44,750	51,409	59,534	69,291	80,416	93,602	36,864	43,073	47,226	51,651	56,640	62,280	68,677
Paints	17,069	20,094	21,941	23,984	26,249	28,763	31,562	18,885	22,774	24,936	27,356	29,919	32,763	35,699	18,885	22,018	23,520	25,138	26,884	28,771	30,812
Lubes	9,638	10,409	11,241	12,140	13,112	14,161	15,294	9,638	10,409	11,241	12,140	13,112	14,161	15,294	9,638	10,119	10,625	11,157	11,714	12,300	12,915
F&F	9,550	12,655	16,134	20,112	25,083	31,294	39,054	8,341	10,967	14,272	18,598	24,100	30,684	38,959	8,341	10,336	12,361	14,493	17,004	19,965	23,457
Pharma IBM	-	400	640	896	1,120	1,344	1,613	-	600	960	1,440	2,160	2,808	3,650	-	600	720	864	1,037	1,244	1,493
EBITDA/kg (Rs)	37	41	42	43	45	46	47	38	41	44	46	48	49	51	38	41	43	43	44	45	46
EBITDA	1,356	1,766	2,107	2,481	2,921	3,449	4,091	1,388	1,842	2,237	2,710	3,306	3,962	4,760	1,388	1,771	2,012	2,239	2,500	2,798	3,140
Depreciation	385	422	468	528	588	648	708	385	422	468	528	588	648	708	385	422	468	528	588	648	708
EBIT	972	1,344	1,638	1,952	2,333	2,801	3,383	1,004	1,420	1,768	2,182	2,718	3,314	4,051	1,004	1,349	1,543	1,711	1,911	2,150	2,432
PBT	917	1,297	1,600	1,912	2,289	2,750	3,323	949	1,374	1,729	2,141	2,673	3,264	3,992	949	1,303	1,504	1,670	1,867	2,099	2,372
APAT	688	973	1,200	1,434	1,716	2,063	2,492	712	1,030	1,297	1,606	2,005	2,448	2,994	712	977	1,128	1,253	1,400	1,575	1,779
EPS	20.8	29.5	36.3	43.4	52.0	62.5	75.5	21.6	31.2	39.3	48.6	60.7	74.1	90.6	21.6	29.6	34.2	37.9	42.4	47.7	53.9
Capital employed	6,787	7,227	8,005	8,945	10,088	11,484	13,200	6,802	7,262	8,063	9,049	10,261	11,715	13,501	6,802	7,230	7,962	8,837	9,898	11,191	12,772
ROCE (pre-Tax)	14.3%	19.2%	21.5%	23.0%	24.5%	26.0%	27.4%	14.8%	20.2%	23.1%	25.5%	28.1%	30.2%	32.1%	14.8%	18.7%	19.4%	19.4%	19.3%	19.2%	19.0%

TP @ PE bands	1-yr TP			3-yr TP			5-yr TP			1-yr TP			3-yr TP			5-yr TP		
	CAGR			CAGR			CAGR			CAGR			CAGR			CAGR		
22	800			1,100			1,700			900			1,300			2,000		
25	900			1,300			1,900			1,000			1,500			2,300		
30	1,100			1,600			2,300			1,200			1,800			2,700		
Upside from CMP	CAGR			CAGR			CAGR			CAGR			CAGR			CAGR		
22x PE	-5%			9%			15%			6%			15%			19%		
25x PE	6%			15%			18%			18%			21%			22%		
30x PE	30%			24%			22%			42%			29%			26%		

Exhibit 32: 1-year forward PE trend


Source: Bloomberg, Nirmal Bang Institutional Equities Research

Financials

Exhibit33: Income statement

Y/E March (Rsmn)	FY22	FY23	FY24E	FY25E	FY26E
Net Sales	6,315	7,299	7,097	8,717	10,238
Growth YoY%	31.9	15.6	-2.8	22.8	17.4
COGS	3,766	4,360	4,329	5,230	6,040
Gross margin %	40.4	40.3	39.0	40.0	41.0
Staff costs	387	436	412	523	614
Other expenses	955	1,149	1,000	1,198	1,476
EBITDA	1,207	1,354	1,356	1,766	2,107
Growth YoY%	25.8	12.2	0.1	30.2	19.3
EBITDA margin %	19.1	18.6	19.1	20.3	20.6
Depreciation	264	302	385	422	468
EBIT	943	1,052	972	1,344	1,638
Interest	93	39	69	64	61
Other income	16	14	15	18	22
PBT (bei)	865	1,027	917	1,297	1,600
PBT	865	1,027	917	1,297	1,600
ETR	26.4	21.7	25.0	25.0	25.0
PAT	637	804	688	973	1,200
Adj PAT	637	804	688	973	1,200
Growth YoY%	30.2	26.4	-14.5	41.4	23.3

Source: Company, Nirmal Bang Institutional Equities Research

Exhibit 35: Balance sheet

Y/E March (Rsmn)	FY22	FY23	FY24E	FY25E	FY26E
Share capital	156	166	166	166	166
Reserves	4,415	5,421	5,834	6,418	7,138
Net worth	4,571	5,587	6,000	6,584	7,303
Long term debt	186	338	500	500	500
Short term debt	254	135	288	144	201
Total debt	440	473	788	644	701
Other non-current liabilities	188	249	324	421	547
Total Equity & Liabilities	5,200	6,309	7,111	7,648	8,552
Gross block	4,135	5,006	6,306	7,306	8,306
Accumulated depreciation	1,545	1,321	1,706	2,128	2,596
Net Block	2,626	3,760	4,676	5,254	5,785
CWIP	138	167	167	83	42
Intangible and others	-	-	-	-	-
Other non-current assets	98	120	144	144	173
Investments	171	517	258	258	362
Trade receivables	1,430	1,234	1,167	1,433	1,683
Inventories	959	852	778	955	1,122
Cash & Cash equivalents	163	64	453	207	253
Other current assets	155	243	170	204	245
Total current assets	2,707	2,392	2,567	2,799	3,302
Trade payables	317	333	292	358	421
Other current liabilities	225	315	409	532	692
Total current liabilities	542	648	701	890	1,112
Total Assets	5,200	6,309	7,111	7,648	8,552

Source: Company, Nirmal Bang Institutional Equities Research

Exhibit 34: Cash flow

Y/E March (Rsmn)	FY22	FY23	FY24E	FY25E	FY26E
PBT	865	1,027	917	1,297	1,600
Depreciation	269	309	385	422	468
Interest	93	39	69	64	61
Other adjustments	-7	-5	-15	-18	-22
Change in Working capital	-996	461	267	-289	-235
Tax paid	-199	-241	-229	-324	-400
Operating cash flow	25	1,590	1,394	1,153	1,472
Capex	-531	-1,474	-1,300	-917	-958
Free cash flow	-506	116	94	236	513
Other investing activities	-17	-10	265	18	-111
Investing cash flow	-548	-1,483	-1,035	-899	-1,069
Issuance of share capital	17	10	-	-	-
Movement of Debt	752	191	315	-144	58
Dividend paid (incl DDT)	-113	-260	-275	-389	-480
Other financing activities	-95	-39	5	33	66
Financing cash flow	561	-99	45	-500	-357
Net change in cash flow	38	8	404	-246	46
Opening C&CE	3	41	49	453	207
Closing C&CE	41	49	453	207	253

Source: Company, Nirmal Bang Institutional Equities Research

Exhibit36: Key ratios

Y/E March	FY22	FY23	FY24E	FY25E	FY26E
Per share (Rs)					
Adj EPS	22.5	24.2	20.8	29.5	36.3
Book value	161.9	168.4	181.6	199.3	221.1
DPS	8.0	6.0	8.3	11.8	14.5
Valuation (x)					
P/Sales	3.8	3.8	3.9	3.2	2.7
EV/sales	3.8	3.9	4.0	3.2	2.8
EV/EBITDA	19.9	20.9	20.8	16.0	13.4
P/E	37.4	34.7	40.4	28.6	23.2
P/BV	5.2	5.0	4.6	4.2	3.8
Return ratios (%)					
RoCE	16.0	14.9	11.3	14.4	16.1
RoCE (pre-tax)	21.8	19.0	15.1	19.2	21.5
RoE	17.9	15.8	11.9	15.5	17.3
Profitability ratios (%)					
Gross margin	40.4	40.3	39.0	40.0	41.0
EBITDA margin	19.1	18.6	19.1	20.3	20.6
PAT margin	10.1	11.0	9.7	11.1	11.7
Liquidity ratios (%)					
Current ratio	3.7	2.4	2.1	2.0	2.0
Quick ratio	2.4	1.6	1.5	1.3	1.4
Solvency ratio (%)					
Debt to Equity ratio	0.1	0.1	0.1	0.1	0.1
Net Debt to Equity	0.1	0.1	0.1	0.1	0.1
Turnover ratios					
Fixed asset turnover ratio (x)	1.6	1.6	1.3	1.3	1.3
Debtor days	83	62	60	60	60
Inventory days	55	43	40	40	40
Creditor days	18	17	15	15	15
Net Working capital days	120	88	85	85	85


Source: Company, Nirmal Bang Institutional Equities Research

Rating track

Date	Rating	Market price (Rs)	Target price (Rs)
26 April 2017	Buy	259	351
31 May 2017	Buy	287	387
8 September 2017	Buy	302	381
15 November 2017	Buy	315	426
7 February 2018	Buy	325	460
1 June 2018	Buy	321	450
6 August 2018	Buy	307	450
13 November 2018	Buy	266	400
31 January 2019	Buy	219	400
8 June 2020	Buy	195	300
1 August 2020	Buy	229	300
13 November 2020	Buy	295	400
9 December 2020	Buy	288	400
7 January 2021	Buy	319	450
19 January 2021	Buy	323	500
26 May 2021	Buy	488	570
28 July 2021	Buy	504	600
24 September 2021	Buy	540	650
30 September 2021	Buy	585	680
1 November 2021	Buy	668	800
27 January 2022	Buy	705	860
9 May 2022	Buy	704	840
27 July 2022	Buy	760	880
19 September 2022	Accumulate	993	1,000
8 November 2022	Accumulate	939	1,000
6 February 2023	Accumulate	1,063	1,050
22 February 2023	Accumulate	946	1,050
22 March 2023	Buy	930	1,120
03 May 2023	Buy	994	1,150
09 June 2023	Buy	972	1,150
05 August 2023	Buy	1,000	1,150
21 September 2023	Buy	927	1,200
08 November 2023	Buy	878	1,100
09 February 2024	Buy	880	1,040
06 March 2024	Buy	846	1,100

The coverage was transferred to Abhishek Navalgund w.e.f 8th Jun 2020

Rating track graph



DISCLOSURES

This Report is published by Nirmal Bang Equities Private Limited (hereinafter referred to as “NBEPL”) for private circulation. NBEPL is a registered Research Analyst under SEBI (Research Analyst) Regulations, 2014 having Registration no. INH000001436. NBEPL is also a registered Stock Broker with National Stock Exchange of India Limited and BSE Limited in cash and derivatives segments.

NBEPL has other business divisions with independent research teams separated by Chinese walls, and therefore may, at times, have different or contrary views on stocks and markets.

NBEPL or its associates have not been debarred / suspended by SEBI or any other regulatory authority for accessing / dealing in securities Market. NBEPL, its associates or analyst or his relatives do not hold any financial interest in the subject company. NBEPL or its associates or Analyst do not have any conflict or material conflict of interest at the time of publication of the research report with the subject company. NBEPL or its associates or Analyst or his relatives do not hold beneficial ownership of 1% or more in the subject company at the end of the month immediately preceding the date of publication of this research report.

NBEPL or its associates / analyst has not received any compensation / managed or co-managed public offering of securities of the company covered by Analyst during the past twelve months. NBEPL or its associates have not received any compensation or other benefits from the company covered by Analyst or third party in connection with the research report. Analyst has not served as an officer, director or employee of Subject Company and NBEPL / analyst has not been engaged in market making activity of the subject company.

Analyst Certification: I, Abhishek Navalgund, research analyst the author of this report, hereby certify that the views expressed in this research report accurately reflects my/our personal views about the subject securities, issuers, products, sectors or industries. It is also certified that no part of the compensation of the analyst was, is, or will be directly or indirectly related to the inclusion of specific recommendations or views in this research. The analyst is principally responsible for the preparation of this research report and has taken reasonable care to achieve and maintain independence and objectivity in making any recommendations.

Disclaimer

Stock Ratings Absolute Returns

BUY > 15%

ACCUMULATE -5% to 15%

SELL < -5%

This report is for the personal information of the authorized recipient and does not construe to be any investment, legal or taxation advice to you. NBEPL is not soliciting any action based upon it. Nothing in this research shall be construed as a solicitation to buy or sell any security or product, or to engage in or refrain from engaging in any such transaction. In preparing this research, we did not take into account the investment objectives, financial situation and particular needs of the reader.

This research has been prepared for the general use of the clients of NBEPL and must not be copied, either in whole or in part, or distributed or redistributed to any other person in any form. If you are not the intended recipient you must not use or disclose the information in this research in any way. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. NBEPL will not treat recipients as customers by virtue of their receiving this report. This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject NBEPL & its group companies to registration or licensing requirements within such jurisdictions.

The report is based on the information obtained from sources believed to be reliable, but we do not make any representation or warranty that it is accurate, complete or up-to-date and it should not be relied upon as such. We accept no obligation to correct or update the information or opinions in it. NBEPL or any of its affiliates or employees shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. NBEPL or any of its affiliates or employees do not provide, at any time, any express or implied warranty of any kind, regarding any matter pertaining to this report, including without limitation the implied warranties of merchantability, fitness for a particular purpose, and non-infringement. The recipients of this report should rely on their own investigations.

This information is subject to change without any prior notice. NBEPL reserves its absolute discretion and right to make or refrain from making modifications and alterations to this statement from time to time. Nevertheless, NBEPL is committed to providing independent and transparent recommendations to its clients, and would be happy to provide information in response to specific client queries.

Before making an investment decision on the basis of this research, the reader needs to consider, with or without the assistance of an adviser, whether the advice is appropriate in light of their particular investment needs, objectives and financial circumstances. There are risks involved in securities trading. The price of securities can and does fluctuate, and an individual security may even become valueless. International investors are reminded of the additional risks inherent in international investments, such as currency fluctuations and international stock market or economic conditions, which may adversely affect the value of the investment. Opinions expressed are subject to change without any notice. Neither the company nor the director or the employees of NBEPL accept any liability whatsoever for any direct, indirect, consequential or other loss arising from any use of this research and/or further communication in relation to this research. Here it may be noted that neither NBEPL, nor its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profit that may arise from or in connection with the use of the information contained in this report.

Copyright of this document vests exclusively with NBEPL.

*"Registration granted by SEBI and certification from NISM in no way guarantee the performance of the intermediary or provide any assurance of returns to investors."

Our reports are also available on our website www.nirmalbang.com

Access all our reports on Bloomberg, Thomson Reuters and Factset.

Team Details:

Name		Email Id	Direct Line
Rahul Arora	CEO	rahul.arora@nirmalbang.com	-
Krishnan Sambamoorthy	Head of Research	krishnan.s@nirmalbang.com	+91 22 6273 8210
Dealing			
Ravi Jagtiani	Dealing Desk	ravi.jagtiani@nirmalbang.com	+91 22 6273 8230, +91 22 6636 8833
Michael Pillai	Dealing Desk	michael.pillai@nirmalbang.com	+91 22 6273 8102/8103, +91 22 6636 8830

Nirmal Bang Equities Pvt. Ltd.

Correspondence Address

B-2, 301/302, Marathon Innova,
 Nr. Peninsula Corporate Park,
 Lower Parel (W), Mumbai-400013.
 Board No. : 91 22 6273 8000/1; Fax. : 022 6273 8010